Publications

All      Ay      Benedict       Cheroutre       Croft       Crotty      Einav       Grifoni       Hogan       Kronenberg      Lisdestam Arlehamn      Myers      Peters      Rao      Reina      Saphire      Schmiedel      Schoenberger      Sette      Sharma      Shresta      Vijayanand      Weiskopf
Altman             Eschweiler      Hedrick       Kawakami      Ley      Pandurangan      Seumois      Von Herrath      
Mar 19, 2025
  • Vaccine

Impact in the humoral and cellular immune response to SARS-CoV-2 variants after primary vaccination with AZD1222/COVISHIELD protocol in healthy adults

Capão A, Araújo MF, Tort LFL, Toledo TS, Oliveira ACA, Caetano BC, Resende PC, Martins-Filho OA, Ribeiro-Alves M, Grifoni A, Weiskopf D, Sette A, Siqueira MM, Côrtes FH, Garcia CC
Jan 9, 2025
  • bioRxiv [Preprint]

Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters.

da Silva Antunes R, Fajardo-Rosas V, Yu ED, Gálvez RI, Abawi A, Alexandar Escarrega E, Martínez-Pérez A, Johansson E, Goodwin B, Frazier A, Dan JM, Crotty S, Seumois G, Weiskopf D, Vijayanand P, Sette A
Feb 24, 2025
  • JCI Insight

Frequency of dengue virus-specific T cells is related to infection outcome in endemic settings

Gálvez RI, Martínez-Pérez A, Escarrega EA, Singh T, Zambrana JV, Balmaseda Á, Harris E, Weiskopf D
Jan 16, 2025
  • Curr Pharm Biotechnol

A Roadmap Towards the Identification and Validation of Conserved T Cell Epitope Regions in Viral Pathogen Families with Pandemic Potential

Grifoni A, Sidney J, Weiskopf D, Scheuermann RH, Sette A
Mar 24, 2025
  • J Natl Cancer Inst

In the time of COVID-19: challenges, successes and lessons learned from studies in cancer patients

Mack PC, Crawford JM, Chang A, Yin A, Klein SL, Shea P, Hirsch FR, Zidar D, Simon V, Gleason C, McBride R, Cordon-Cardo C, VanOudenhove J, Halene S, Lee FE, Mantis N, Kushi LH, Weiskopf D, Merchant A, Reckamp KL, Skarbinski J, Figueiredo JC
Jan 12, 2025
  • Vaccine

Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: A randomised, comparator-controlled, phase 2 trial

Thiem VD, Anh DD, Ha VH, Van Thom N, Thang TC, Mateus J, Carreño JM, Raghunandan R, Huong NM, Mercer LD, Flores J, Escarrega EA, Raskin A, Thai DH, Van Be L, Sette A, Innis BL, Krammer F, Weiskopf D